Book a Meeting

Highly Galactosylated Anti-IL-23 p19 (Tildrakizumab) Antibody (CAT#: BioBet-GA-052ZP) Datasheet

Target
IL-23 p19
Isotype
IgG1
Description
The Highly Galactosylated Anti-IL-23 p19 (Tildrakizumab), a biobetter antibody contains with a high level of galactosylation.
Indication
Plaque psoriasis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL-23 p19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL-23 p19
Full Name
IL-23 p19
Alternative Names
IL-23 p19
Cellular Localization
Extracellular region or secreted
Genecards
15488
Involvement in Disease
Its related pathways are Tuberculosis and PEDF Induced Signaling.
Related Pathways
Combined with IL12B to form IL-23 interleukin, which is a heterodimeric cytokine that plays a role in innate immunity and adaptive immunity. IL-23 and IL-17 may constitute an acute response to surrounding tissue infection. IL-23 binds to the heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory instead of naive T cells, and promotes the production of pro-inflammatory cytokines. IL-23 induces autoimmune inflammation, so it may be the cause of autoimmune inflammatory diseases and may be important for tumor occurrence.
Field of research
No Post-translational modifications
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Tildrakizumab
Host
Humanized
Species Reactivity
Human
Description
Tildrakizumab is a high-affinity, humanized IgG1κ antibody directed against interleukin 23 p19. This product was used for the treatment of moderate to severe plaque psoriasis.
Indication
Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Plaque Psoriasis

Related Products

BetterBet™ Anti-IL-23 p19 Recycling Antibody (CAT#: AES-0622-ZP276)
Highly Galactosylated Anti-IL-23 p19 (Guselkumab) Antibody (CAT#: BioBet-GA-046ZP)
Highly Galactosylated Anti-IL-23 p19 (Risankizumab) Antibody (CAT#: BioBet-GA-054ZP)
BetterBet™ Anti-IL-23 p19 Half-Life Extended Antibody (CAT#: AES-0622-ZP1260)
BetterBet™ Anti-IL-23 p19 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP604)
Non-fucosylated Anti-Human IL-23 p19 (Risankizumab) Therapeutic Antibody (CAT#: BioBet-054ZP)
Non-fucosylated Anti-Human IL-23 p19 (Tildrakizumab) Therapeutic Antibody (CAT#: BioBet-052ZP)
Non-fucosylated Anti-Human IL-23 p19 (Guselkumab) Therapeutic Antibody (CAT#: BioBet-046ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.